This segment focuses on the development and commercialization of diagnostic tests for the detection and monitoring of minimal residual disease (MRD) in patients with various hematological cancers, including multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia. The core technology utilizes immunosequencing to identify and quantify cancer cells that remain after treatment, enabling clinicians to assess treatment efficacy and predict relapse. Research and development activities include assay optimization, clinical validation, and expansion of the test menu to cover additional cancer types. The clonoSEQ assay is a key product in this segment, providing highly sensitive and specific MRD detection. Patient impact is significant, as early detection of MRD can guide treatment decisions and improve patient outcomes. Market positioning is strong, with clonoSEQ being a leading MRD test. Future opportunities include expanding into solid tumors and developing companion diagnostics. Regulatory aspects involve CLIA validation and FDA submissions. Partnerships with NeoGenomics expand access to personalized disease monitoring for blood cancer patients.

This segment encompasses the development and application of Adaptive Biotechnologies' immune medicine platform for drug discovery, translational research, and the development of novel therapeutics. The core technology is based on immunosequencing, which analyzes the adaptive immune system's T-cell and B-cell receptors to identify disease-specific targets and monitor immune responses. Research and development activities include target discovery, assay development, and clinical validation of diagnostic tests. The immunoSEQ platform is used for translational research, while immunoSEQ T-MAP COVID is used to measure the T-cell immune response to vaccines. The company has strategic collaborations with Genentech for the development of neoantigen-directed T-cell therapies and with Microsoft to develop diagnostic tests for early disease detection. This segment aims to improve patient outcomes by enabling precision medicine approaches and accelerating the development of new therapies. Market positioning is strong due to the company's unique technology and partnerships. Future opportunities include expanding into new therapeutic areas and developing companion diagnostics. Regulatory aspects involve FDA submissions and clinical trials. The company is also collaborating with AstraZeneca to investigate the use of immunoSEQ T-MAP.